2018 Webinar: Controversies in Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
Despite expert consensus that patients with localized but not clearly resectable pancreatic ductal adenocarcinoma (PDAC) should receive some form of neoadjuvant therapy, this intervention is not uniformly practiced. Resection without neoadjuvant therapy frequently results in positive margins, early recurrence, and reduced survival.
This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with pancreatic cancer.
At the conclusion of this activity, participants should be able to:
- Identify benefits of neoadjuvant therapy in patients with borderline resectable pancreatic cancer
- Compare options for neoadjuvant therapy
- Summarize criteria for surgical resection following neoadjuvant therapy
The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Society of Surgical Oncology designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The SSO has approved this activity for up to 1 self¬ assessment credit which meets the requirement of the self¬-assessment component of the American Board of Surgery (ABS) Continuous Certification Program.
Requirements for Earning Credit and Method of Participation
This online activity consists of a webinar, a self-assessment exam, and an evaluation. To receive AMA PRA Category 1 Credit™ and self-assessment credit, participants must watch the webinar, successfully complete the self-assessment exam, and achieve a minimum score of 75% on the exam. The self-assessment exam includes 4 multiple choice questions. Learners will be asked to read each question, select an answer, and review the section of the webinar where the answer is found. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a post-activity evaluation. A certificate of credit will be available upon successful submission of the post-activity evaluation.
Estimated Time to Complete Activity
The estimated time to complete this entire activity is 1 hour.
November 26, 2018
November 26, 2019
The faculty for this activity are listed below:
Clifford S. Cho, MD (Moderator)
University of Michigan Medicine
Robert A. Wolff, MD (Speaker)
MD Anderson Cancer Center
Theodore S. Hong, MD (Speaker)
Massachusetts General Hospital
Cristina R. Ferrone, MD (Speaker)
Massachusetts General Hospital
In accordance with the ACCME’s Accreditation Criteria, the Society of Surgical Oncology must ensure that anyone in position to control the content of this educational activity has disclosed all financial relationships with a commercial interest. All educational planners, authors, reviewers, and other individuals in a position to control or influence the content of this activity were required to disclose all financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.
The ACCME also requires that the Society of Surgical Oncology resolve any reported conflict of interest and ensure the educational content of this activity is vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.
All identified conflicts of interests have been resolved.
Clifford S. Cho, MD has disclosed no relevant disclosures.
Robert A. Wolff, MD: Other - Royalties from MCGraw Hill.
Theodore S. Hong, MD: Advisory Board - EMD Serono; Research - Taiho, BMS, Novartis, Astra-Zeneca.
Cristina R. Ferrone has disclosed no relevant conflicts of interest.
Planners, Reviewers, and Staff
Cletus Arciero, MD, CME/CPD Committee Reviewer, has disclosed no relevant financial relationships.
Jennifer LaFemina, MD, CME/CPD Committee Reviewer, has disclosed no relevant financial relationships.
Alanna Persaud, Program Manager, Society of Surgical Oncology, has disclosed no relevant financial relationships.
Kelley Gazer, Education Coordinator, Society of Surgical Oncology, has disclosed no relevant financial relationships.
The primary purpose of the Society of Surgical Oncology's enduring material is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.
Disclosure of Unlabeled Use
This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.
Privacy and Confidentiality
This activity is partially supported by Celgene.
Mobile Viewing Requirements
Android Smartphones: Android 2.3+ with Adobe Flash Player 10.2 or better installed
Apple Devices: iOS 4+
Online Viewing Requirements
Required Hardware and Software: Screen resolution of 1024X768 or larger, Sound card and speakers/headphones
Microsoft Internet Explorer 7.0 or better
Mozilla Firefox 4 or better
Safari 5 or better
Operating System: Windows 7; Windows Vista; Windows XP Service Pack 2 or 3
X86 or x64 (Browsers must be in 32-bit mode) 1.6-gigahertz (GHz) or higher processor
512MB of RAM
Operating System: Apple Mac OS X 10.4.8 or above
Intel Core™ Duo 1.83GHz or faster processor
512MB of RAM
For technical support, please contact us.